



# 5th International Electronic Conference on Medicinal Chemistry

1-30 November 2019

chaired by Dr. Jean Jacques Vanden Eynde

sponsored by



pharmaceuticals

## New chalcone derivatives with suitable drug-like lipophilicity targeting mitosis

Patrícia Pinto<sup>a,#</sup>, Carmen Mariana Machado<sup>a,#</sup>, Joana Moreira<sup>a,b,#</sup>, José Diogo P. Almeida<sup>c</sup>, Patrícia M. A. Silva<sup>c</sup>, Ana C. Henriques<sup>c</sup>, José Soares<sup>d</sup>, Jorge Salvador<sup>e</sup>, Carlos Afonso<sup>a,b</sup>, Madalena Pinto<sup>a,b</sup>, H. Bousbaa<sup>c,\*</sup>, Honorina Cidade<sup>\*</sup>

<sup>a</sup>Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal

<sup>b</sup>Centro Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR), Universidade do Porto, Portugal

<sup>c</sup>CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde (IINFACETS), Portugal.

<sup>d</sup>LAQV-REQUIMTE, Laboratório de Química Aplicada, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal

<sup>e</sup>Laboratório de Química Farmacêutica e Centro de Neurociências e Biologia celular, Faculdade de Farmácia, Universidade de Coimbra, Pólo III - Polo das Ciências da Saúde, Portugal


#Authors contributed equally to this work

\* Corresponding author: [hcidade@ff.up.pt](mailto:hcidade@ff.up.pt)



# New chalcone derivatives with suitable drug-like lipophilicity targeting mitosis



## 1. Synthesis




## 2. Human Tumor Cell lines

Compounds 3, 5, 9, 11, 15-19 GI<sub>50</sub> < 10 μM

15-17 exhibited antimitotic activity



## 3. Lipophilicity evaluation



Most potent compounds (GI<sub>50</sub> < 8 μM)

3.30 < log K<sub>p</sub> < 3.68



## Abstract:

Chalcones are natural flavonoid precursors that have been reported for their wide range of biological activities, namely antitumor [1-2]. In addition, the presence of an  $\alpha,\beta$ -unsaturated ketone moiety makes these compounds a valuable chemical substrate for the synthesis of bioactive derivatives, such as pyrazoles [3]. Our research group has reported two synthetic chalcone derivatives with antimitotic effect [4-5]. Hence, in continuation of our efforts to obtain new chalcone derivatives with improved antitumor and antimitotic activity, a small library of chalcone derivatives, including pyrazole and  $\alpha,\beta$ -epoxide, was synthesized and evaluated for their cell growth inhibitory activity in three human tumor cell lines. Additionally, their lipophilicity using liposomes as a biomimetic membrane model was determined. From this work, nine chalcones showing suitable drug-like lipophilicity with antimitotic effect were identified. Moreover, one of the compounds was able to enhance chemosensitivity of tumor cells to paclitaxel in NCI-H460 cells.

**Keywords:** Chalcone derivatives; lipophilicity; mitosis






# Introduction: Microtubules Targeting Agents (MTAs)

## Stabilizers


## Destabilizers

Taxane binding site

Colchicine binding site



Vinca alkaloids binding site



Disadvantages  
of MTAs

Hematopoietic toxicity

Neurologic toxicity

Drug resistance



New Antimitotic agents



5th International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2019

sponsors:



pharmaceuticals

## Biological Activities


Anti-inflammatory

Anti-tuberculosis

Antidiabetic

Antimicrobial

Antioxidant



Cardiovascular agents

Antiulcer

Antitumor

### Molecular targets

p53/MDM2 interaction

Sex hormones

mTOR pathway

NF-Kb pathway

Oxireductases

ABC transporters

Microtubules – Tubulin Polymerization

Antimicrobial

Antileishmanial

Antimalarial

Singh, P.; Anand, A.; Kumar, V. *Eur. J. Med. Chem.* 2014, 85, 758-777.




5th International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2019

sponsors:




pharmaceuticals

Chalcones with antimitotic effect previously reported by our research group:



1



PC2 (2)

Caused abnormal spindle apparatus assembly

Prolonged mitotic arrest followed by cell death

Masawang K. *et al.*, *Toxicol. Lett.* 2014, 229, 393-401. Fonseca J. *et al.*, *Molecules* 2016, 21, 982



5th International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2019

sponsors:



pharmaceuticals




## Aims

To obtain new chalcone derivatives with promising antimitotic effect with suitable drug-like lipophilicity

- Synthesis of a small library of chalcones, structure related with **1** and **PC2 (2)**
- Synthesis of pyrazole derivatives
- Evaluate the growth inhibitory effect of all synthesized chalcone derivatives
- Assess the antimitotic effect of the most promising chalcone derivatives
- Determine lipophilicity of all synthesized chalcone derivatives




## Synthesis of Chalcones






## Synthesis of Pyrazole Derivatives



**3** R= H  
**9** R= CH<sub>3</sub>


H<sub>2</sub>O<sub>2</sub>, 5% NaOH,  
 CH<sub>3</sub>COCH<sub>3</sub> : CH<sub>3</sub>OH (3:2),  
 r.t., 2-3 h;

### Chalcone epoxide



**24** η= 61 %  
**25** η= 58 %

NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O,  
*p*-toluenesulfonic acid, Xylenes  
 and dichloromethane,  
 100 °C, 3-5 h



**26** η= 4 %  
**27** η= 1 %



## Evaluation of the Antiproliferative Activity


|    | GI <sub>50</sub> (μM) |              |              |
|----|-----------------------|--------------|--------------|
|    | A375-C5               | MCF-7        | NCI-H460     |
| 3  | 3.63 ± 0.58           | 5.95 ± 0.88  | 5.06 ± 0.20  |
| 4  | 11.12 ± 0.96          | 12.60 ± 2.68 | 13.62 ± 2.61 |
| 5  | 4.15 ± 0.85           | 7.70 ± 2.32  | 7.12 ± 0.20  |
| 6  | 17.77 ± 5.08          | 23.92 ± 7.18 | 17.76 ± 2.97 |
| 7  | 5.37 ± 1.47           | 11.65 ± 4.57 | 8.34 ± 2.02  |
| 8  | 7.25 ± 2.97           | 12.12 ± 2.33 | 8.44 ± 2.13  |
| 9  | 3.21 ± 0.45           | 3.26 ± 0.11  | 3.02 ± 0.01  |
| 10 | 6.96 ± 0.65           | 10.06 ± 3.70 | 7.48 ± 0.41  |
| 11 | 3.33 ± 1.18           | 4.28 ± 2.17  | 4.44 ± 0.87  |
| 12 | 11.27 ± 1.30          | 10.78 ± 4.44 | 15.28 ± 2.85 |
| 13 | 7.14 ± 1.87           | 12.17 ± 2.79 | 11.85 ± 3.46 |
| 14 | 12.14 ± 1.87          | 22.54 ± 1.84 | 15.50 ± 5.66 |
| 15 | 5.70 ± 1.45           | 5.56 ± 1.51  | 6.28 ± 0.31  |

|    | GI <sub>50</sub> (μM) |               |              |
|----|-----------------------|---------------|--------------|
|    | A375-C5               | MCF-7         | NCI-H460     |
| 16 | 6.90 ± 1.10           | 6.89 ± 0.41   | 6.61 ± 0.63  |
| 17 | 8.57 ± 1.06           | 9.75 ± 1.24   | 8.35 ± 0.31  |
| 18 | 2.89 ± 0.19           | 3.97 ± 0.82   | 5.60 ± 1.20  |
| 19 | 7.10 ± 0.62           | 8.52 ± 1.03   | 8.74 ± 1.03  |
| 20 | 3.45 ± 0.54           | 6.49 ± 0.30   | 10.84 ± 1.92 |
| 21 | 3.81 ± 0.765          | 13.15 ± 0.44  | 8.95 ± 1.01  |
| 22 | 4.51 ± 1.30           | 8.41 ± 3.63   | 9.61 ± 2.54  |
| 23 | 4.14 ± 0.70           | 15.10 ± 0.39  | 27.68 ± 1.91 |
| 24 | 38.50 ± 4.26          | 59.92 ± 12.70 | 61.78 ± 2.04 |
| 25 | 6.63 ± 3.37           | 14.01 ± 1.73  | 16.88 ± 3.48 |
| 26 | > 37.5                | > 37.5        | > 37.5       |
| 27 | 16.08 ± 2.94          | 16.34 ± 1.40  | 16.15 ± 0.56 |

GI<sub>50</sub> values (concentration that causes 50% of growth inhibitory effect) in tumour cells. Cells were treated for 48 h and analysed with the sulforhodamine B assay.



## NCI-H460 cells arrest in mitosis, in response to most potent compounds treatment




**Figure 1.** Mitotic Index graph showing accumulation of mitotic cells after 15 h of compound treatment with all selected compounds. Statistical significance of samples treated with the compounds when compared with control (\* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ ). Data represent mean $\pm$ SD of three independent experiments.



## NCI-H460 cells arrest in mitosis, in response to 15, 16 and 17 treatment

15 h




**Figure 2.** Treatment with **15**, **16** and **17** arrests NCI-H460 cells in mitosis. Phase contrast microscopy images showing an accumulation of rounded-mitotic cells (Bar= 20 µm).



## NCI-H460 cells arrest in mitosis, in response to 15, 16 and 17 treatment


15 h



**Figure 3.** 15, 16 and 17 treatment arrests NCI-H460 cells in mitosis, as shown with DAPI staining of DNA (Bar=5  $\mu$ m).




## Mitotic Spindle Morphology



**Figure 4.** (a) **15** treatment affects mitotic spindle morphology. Immunofluorescence staining with anti- $\alpha$ -tubulin antibody. DNA was stained with DAPI (blue). Bar = 5  $\mu$ m. (b) Multipolar mitotic spindle graph showing the percentage of multipolar mitotic spindle in mitotic cells, by 15 hours treatment with **15**. Statistical significance of samples with **15** when compared with control (\* $P < 0.05$ ). Data represent mean  $\pm$  SD of three independent experiments. The same result was obtained for **16** and **17** treatment.




## Compound 15 combined treatment with Paclitaxel (Tx)



**Figure 5.** The concentrations of Tx used were from 1 nM to 25 nM as indicated. As control were considered untreated cells. The concentration of Tx at 25 and 2.5 nM with 6.28 μM of **15** presented statistical significance (\* $p < 0.05$ ), Tx at 10 and 5 nM with 6.28 μM of **15** was significant (\*\* $p < 0.005$ ). Tx at 1 nM combined with 6.28 μM of **15** had statistical significance (\*\*\*\* $p < 0.0001$ ). Data are means  $\pm$  SD from at least three independent experiments.



## Prediction vs determination of Log P values




**Figure 6.** (a) Mean, median and standard deviation of the Log P predicted by different in silico methods. (b) Experimentally obtained Log K<sub>p</sub> values, and mean and median of predicted log P for the studied chalcones.





## Relationship between Lipophilicity and Antiproliferative activity



**Figure 7.** Comparison between the  $GI_{50}$  of the chalcone derivatives on NCI-H460 cell line and the log  $K_p$ . The insert displays the comparison of the most potent compounds ( $GI_{50} < 8 \mu M$ ) and their molecular weight.

None compounds showing a  $GI_{50} < 10 \mu M$

Most potent compounds ( $GI_{50} < 8 \mu M$ )

log  $K_p$  below 3

$3.30 < \log K_p < 3.68$

Not share the same  
chemical features  
(MW)



## Synthesis

- 25 chalcone derivatives were synthesized
- **7, 9, 10, 13-17** and **24-27** were described for the first time

## Biological Activity

- Chalcones **3, 5, 9, 11, 15-19**, and **22** demonstrated a potent antiproliferative activity
- Compounds **15-17** emerged as potent antimitotic agents by interfering with mitotic spindle assembly
- Chalcone **15** sensitizes human tumor cells to death by low doses of paclitaxel

## Lipophilicity evaluation

- Most potent compounds ( $GI_{50} < 8 \mu M$ ) have  $log K_p$  values between 3.30 and 3.60
- Similar lipophilicity do not share same chemical properties (MW)



This research was partially supported by the Strategic Funding UID/Multi/04423/2019 and under the project PTDC/SAU-PUB/28736/2017 (reference POCI-01-0145-FEDER-028736), co-financed by COMPETE 2020, Portugal 2020 and the European Union through the ERDF and by FCT through national funds. This work was also supported through funds provided by CESPu, Crl under the project ComeTarget\_CESPu\_2017. Ana Henriques, Joana Moreira and José Soares acknowledge for their FCT grants (SFRH/BD/111365/2015 and SFRH/BD/135852/2018, and SFRH/BD/98105/2013, respectively).

